These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 22863589)
1. [Amplification of γδ T cells in PBMCs of healthy donors and osteosarcoma patients stimulated by zoledronate]. Li ZX; Sun LL; Cheng RL; Sun ZW; Ye ZM Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Aug; 28(8):822-4. PubMed ID: 22863589 [TBL] [Abstract][Full Text] [Related]
2. [Effect of zoledronate on the cytotoxicity of γδ T cells from PBMCs of osteosarcoma patients against osteosarcoma]. Li Z; Tang J; Sun L; Ye Z Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2013 Jan; 29(1):6-9. PubMed ID: 23294710 [TBL] [Abstract][Full Text] [Related]
3. Effect of IL-18 on expansion of gammadelta T cells stimulated by zoledronate and IL-2. Li W; Kubo S; Okuda A; Yamamoto H; Ueda H; Tanaka T; Nakamura H; Yamanishi H; Terada N; Okamura H J Immunother; 2010 Apr; 33(3):287-96. PubMed ID: 20445349 [TBL] [Abstract][Full Text] [Related]
4. Type I IFN-mediated enhancement of anti-leukemic cytotoxicity of gammadelta T cells expanded from peripheral blood cells by stimulation with zoledronate. Watanabe N; Narita M; Yokoyama A; Sekiguchi A; Saito A; Tochiki N; Furukawa T; Toba K; Aizawa Y; Takahashi M Cytotherapy; 2006; 8(2):118-29. PubMed ID: 16698685 [TBL] [Abstract][Full Text] [Related]
5. Essential requirements of zoledronate-induced cytokine and γδ T cell proliferative responses. Nussbaumer O; Gruenbacher G; Gander H; Komuczki J; Rahm A; Thurnher M J Immunol; 2013 Aug; 191(3):1346-55. PubMed ID: 23794630 [TBL] [Abstract][Full Text] [Related]
6. Induction of gamma delta T cells using zoledronate plus interleukin-2 in patients with metastatic cancer. Nagamine I; Yamaguchi Y; Ohara M; Ikeda T; Okada M Hiroshima J Med Sci; 2009 Mar; 58(1):37-44. PubMed ID: 19400555 [TBL] [Abstract][Full Text] [Related]
7. DC-like cell-dependent activation of human natural killer cells by the bisphosphonate zoledronic acid is regulated by γδ T lymphocytes. Nussbaumer O; Gruenbacher G; Gander H; Thurnher M Blood; 2011 Sep; 118(10):2743-51. PubMed ID: 21673342 [TBL] [Abstract][Full Text] [Related]
8. Therapeutic Potential of Ex Vivo Expanded γδ T Cells against Osteosarcoma Cells. Ko Y; Jeong YH; Lee JA Cells; 2022 Jul; 11(14):. PubMed ID: 35883606 [TBL] [Abstract][Full Text] [Related]
9. Zoledronate facilitates large-scale ex vivo expansion of functional gammadelta T cells from cancer patients for use in adoptive immunotherapy. Kondo M; Sakuta K; Noguchi A; Ariyoshi N; Sato K; Sato S; Sato K; Hosoi A; Nakajima J; Yoshida Y; Shiraishi K; Nakagawa K; Kakimi K Cytotherapy; 2008; 10(8):842-56. PubMed ID: 19016372 [TBL] [Abstract][Full Text] [Related]
10. Expression and function of PD-1 in human γδ T cells that recognize phosphoantigens. Iwasaki M; Tanaka Y; Kobayashi H; Murata-Hirai K; Miyabe H; Sugie T; Toi M; Minato N Eur J Immunol; 2011 Feb; 41(2):345-55. PubMed ID: 21268005 [TBL] [Abstract][Full Text] [Related]
11. Gamma delta T cells from HIV+ donors can be expanded in vitro by zoledronate/interleukin-2 to become cytotoxic effectors for antibody-dependent cellular cytotoxicity. Poonia B; Pauza CD Cytotherapy; 2012 Feb; 14(2):173-81. PubMed ID: 22029653 [TBL] [Abstract][Full Text] [Related]
12. [gammadelta T cells stimulated by zoledronate kill osteosarcoma cells]. Jiang H; Xu Q; Yang C; Cao ZG; Li ZX; Ye ZM Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2010 Dec; 26(12):1195-7. PubMed ID: 21138682 [TBL] [Abstract][Full Text] [Related]
13. Zoledronate-activated Vγ9γδ T cell-based immunotherapy is feasible and restores the impairment of γδ T cells in patients with solid tumors. Noguchi A; Kaneko T; Kamigaki T; Fujimoto K; Ozawa M; Saito M; Ariyoshi N; Goto S Cytotherapy; 2011 Jan; 13(1):92-7. PubMed ID: 20831354 [TBL] [Abstract][Full Text] [Related]
14. IL-12 conditioning of peripheral blood mononuclear cells from breast cancer patients promotes the zoledronate-induced expansion of γδ T cells in vitro and enhances their cytotoxic activity and cytokine production. Assy L; Khalil SM; Attia M; Salem ML Int Immunopharmacol; 2023 Jan; 114():109402. PubMed ID: 36481526 [TBL] [Abstract][Full Text] [Related]
15. Osteosarcoma cell line growth inhibition by zoledronate-stimulated effector cells. Muraro M; Mereuta OM; Carraro F; Madon E; Fagioli F Cell Immunol; 2007 Oct; 249(2):63-72. PubMed ID: 18163982 [TBL] [Abstract][Full Text] [Related]
16. Zoledronate stimulates gamma delta T cells in prostate cancer patients. Naoe M; Ogawa Y; Takeshita K; Morita J; Shichijo T; Fuji K; Fukagai T; Iwamoto S; Terao S Oncol Res; 2010; 18(10):493-501. PubMed ID: 20681408 [TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effects of gammadelta T cells expanded ex vivo by a third generation bisphosphonate for cancer immunotherapy. Sato K; Kimura S; Segawa H; Yokota A; Matsumoto S; Kuroda J; Nogawa M; Yuasa T; Kiyono Y; Wada H; Maekawa T Int J Cancer; 2005 Aug; 116(1):94-9. PubMed ID: 15756684 [TBL] [Abstract][Full Text] [Related]
18. Dysregulated CD25 and Cytokine Expression by γδ T Cells of Systemic Sclerosis Patients Stimulated With Cardiolipin and Zoledronate. Migalovich Sheikhet H; Villacorta Hidalgo J; Fisch P; Balbir-Gurman A; Braun-Moscovici Y; Bank I Front Immunol; 2018; 9():753. PubMed ID: 29706966 [TBL] [Abstract][Full Text] [Related]
19. [The comparison between HIV-infected patients' Vdelta2 T cells expansion efficiencies by zoledronic acid and gammadelta TCR monoclonal antibody in vitro]. Xu W; Wu XL; Xie YX; Yang JL; Nie WM; Zhao M; Chen WW Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2012 Dec; 26(6):442-5. PubMed ID: 23627025 [TBL] [Abstract][Full Text] [Related]
20. Impaired function of gamma-delta lymphocytes in melanoma patients. Petrini I; Pacini S; Galimberti S; Taddei MR; Romanini A; Petrini M Eur J Clin Invest; 2011 Nov; 41(11):1186-94. PubMed ID: 22775565 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]